Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 252 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Preserved Ejection Fraction Clear all
Completed Phase 4 Interventional Results available

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction

NCT03506412
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Entresto™ 49Mg-51 mg tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371
View directory record Official record
Conditions
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting No phase listed Observational

Precision Rehabilitation for Veterans With (HFpEF)

NCT07493915
View directory record Official record
Conditions
Heart Failure, Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Columbia VA Health Care System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Active, not recruiting Not applicable Interventional

Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction

NCT05839730
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Concentric Hypertrophy
Interventions
Pacemaker PLR + TRT ON, Pacemaker non-pacing mode or an exertional rate-adaptive pacing mode with no planned pacing at rest.
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Naples, Florida • O'Fallon, Illinois • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Early Phase 1 Interventional

Transthyretin Cardiac Amyloidosis in HFpEF

NCT03414632
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
99mTc-PYP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Physiological Effects of Grape Seed Extract in Diastolic Heart Failure

NCT01185067
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
Interventions
grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting Phase 2 Interventional

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

NCT07202000
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Activin ligand-trap biological therapy, Placebo, Normal Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Active, not recruiting Not applicable Interventional

Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

NCT05136820
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Atrial Flow Regulator, Sham Comparator
Device
Lead sponsor
Occlutech International AB
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

NCT05723679
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Obesity
Interventions
HeO2 gas mixture, Room air gas mixture
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

NCT01951638
View directory record Official record
Conditions
Heart Failure
Interventions
Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 10, 2026, 5:11 AM EDT
Withdrawn Not applicable Interventional

Rivet PVS Therapy in Group 2 PH-HFpEF

NCT05205265
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Rivet Shunt
Device
Lead sponsor
NXT Biomedical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

NCT05174351
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
beta blocker discontinuation
Other
Lead sponsor
UConn Health
Other
Eligibility
50 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 10, 2026, 5:11 AM EDT
Terminated Not applicable Interventional

Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)

NCT04133350
View directory record Official record
Conditions
Sleep Disorder; Breathing-Related, Heart Failure
Interventions
Active Patient Engagement
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction

NCT01932606
View directory record Official record
Conditions
Heart Disease, Heart Failure With Preserved Ejection Fraction, Exercise Intolerance, Pulmonary Hypertension
Interventions
Nitrite, Saline Placebo for Nitrite
Drug
Lead sponsor
Barry Borlaug
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational

Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

NCT06671314
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
42,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Electronic S3 Prediction of Hospital Readmissions for HF Exacerbation

NCT04112849
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions
Measurement of S3 heart sound
Diagnostic Test
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 10, 2026, 5:11 AM EDT
Not listed No phase listed Observational

Exercise Capacity Before and After AF Ablation in Patients With HFpEF

NCT05376748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 110 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 10, 2026, 5:11 AM EDT
Not yet recruiting Not applicable Interventional

Pilot Study of Endoscopic Sleeve Gastroplasty for Obese Patients With Heart Failure and Preserved Ejection Fraction

NCT07798219
View directory record Official record
Conditions
Obesity (BMI>30), Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Endoscopic sleeve gastroplasty (ESG)
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting No phase listed Observational

Purinergic Signaling and the Postmenopausal Heart

NCT06015776
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Gender
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
30 Years to 88 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

NCT05577819
View directory record Official record
Conditions
Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
Interventions
99mTc-pyrophosphate Scintigraphy
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
65 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Terminated Not applicable Interventional

Muscle, Essential Amino Acids, and eXercise in Heart Failure

NCT03312387
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Exercise, Essential Amino Acids, Placebo
Other · Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2019 · Synced Sep 10, 2026, 5:11 AM EDT